To observe the effect of metoprolol combined with trimetazidine on the serum levels of inflammatory factor and immune function in elderly patients with coronary artery heart disease combined with heart failure.

Ninety-four elderly patients with coronary heart disease and heart failure were randomly divided into group A and group B, 47 cases in each group. Group A received metoprolol on the basis of routine treatment, while group B received trimetazidine on the basis of group A. The total effective rate of the two groups was counted, and the levels of CRP, CD4⁺ , CD8⁺ before and after treatment were compared between the two groups.

The total effective rate of group B (95.74%) was higher than that of group A (80.85%), and the difference was statistically significant (P<0.05). After treatment, the CRP level of both groups decreased significantly (P<0.05), while that of group B was lower than that of group A (P<0.05). After treatment, the CD4⁺ level of group B was higher than that of group A (P<0.05).

Metoprolol combined with trimetazidine in the treatment of elderly patients with coronary heart disease complicated with heart failure has a good clinical effect, can effectively reduce inflammation, improve immune function, and has clinical popularization value.